Outpost Medicine Raises $20M in Series A Financing

Outpost Medicine, an Indianapolis and London, UK-based biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, closed a $20m extension of its Series A financing.

Participating in the extension, which brought the total amount raised to $61m, included new investor Takeda Ventures, which joined Frazier Healthcare Partners, Novo Holdings A/S, Vivo Capital, and Adams Street Partners.

Led by newly appointment President and Chief Executive Officer Scott Byrd, who succeeds David Socks, Interim CEO, co-founder and Venture Partner with Frazier Healthcare Partners (who will remain on the board of directors) and Tachi Yamada, M.D., Chairman, Outpost is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of urologic and gastrointestinal disorders.
The company intends to use the proceeds from the Series A extension to shift focus to OP-687, a new class of oral therapy in development for the treatment overactive bladder (OAB) and irritable bowel syndrome (IBS).



Join the discussion